A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 11,928 shares of ITOS stock, worth $98,167. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,928
Previous 11,928 -0.0%
Holding current value
$98,167
Previous $121,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$10.09 - $17.97 $706 - $1,257
-70 Reduced 0.58%
11,928 $121,000
Q2 2024

Jul 29, 2024

BUY
$10.33 - $18.09 $32,766 - $57,381
3,172 Added 35.94%
11,998 $178,000
Q4 2023

Jan 30, 2024

BUY
$8.57 - $11.06 $26,301 - $33,943
3,069 Added 53.31%
8,826 $96,000
Q3 2023

Oct 25, 2023

SELL
$10.95 - $14.6 $10 - $14
-1 Reduced 0.02%
5,757 $63,000
Q2 2023

Aug 07, 2023

BUY
$12.93 - $18.05 $54,810 - $76,513
4,239 Added 279.07%
5,758 $76,000
Q1 2023

May 08, 2023

SELL
$13.02 - $22.62 $6,028 - $10,473
-463 Reduced 23.36%
1,519 $20,000
Q4 2022

Feb 01, 2023

SELL
$17.77 - $21.6 $2,505 - $3,045
-141 Reduced 6.64%
1,982 $38,000
Q1 2022

Apr 21, 2022

SELL
$31.92 - $47.45 $126,243 - $187,664
-3,955 Reduced 65.07%
2,123 $68,000
Q4 2021

Feb 01, 2022

BUY
$26.23 - $47.86 $113,366 - $206,850
4,322 Added 246.13%
6,078 $283,000
Q3 2021

Nov 15, 2021

SELL
$23.91 - $29.58 $23 - $29
-1 Reduced 0.06%
1,756 $47,000
Q2 2021

Jul 30, 2021

BUY
$17.9 - $36.1 $2,076 - $4,187
116 Added 7.07%
1,757 $45,000
Q1 2021

May 03, 2021

BUY
$30.86 - $44.2 $50,641 - $72,532
1,641 New
1,641 $56,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $293M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.